Pages that link to "Q33999520"
Jump to navigation
Jump to search
The following pages link to A booster vaccine expressing a latency-associated antigen augments BCG induced immunity and confers enhanced protection against tuberculosis (Q33999520):
Displaying 23 items.
- Prime-boost approaches to tuberculosis vaccine development (Q27024526) (← links)
- The HyVac4 subunit vaccine efficiently boosts BCG-primed anti-mycobacterial protective immunity (Q28727776) (← links)
- Boosting BCG-primed mice with chimeric DNA vaccine HG856A induces potent multifunctional T cell responses and enhanced protection against Mycobacterium tuberculosis. (Q30376072) (← links)
- Dose of incorporated immunodominant antigen in recombinant BCG impacts modestly on Th1 immune response and protective efficiency against Mycobacterium tuberculosis in mice. (Q34053027) (← links)
- The secreted lipoprotein, MPT83, of Mycobacterium tuberculosis is recognized during human tuberculosis and stimulates protective immunity in mice (Q34261521) (← links)
- Low cost tuberculosis vaccine antigens in capsules: expression in chloroplasts, bio-encapsulation, stability and functional evaluation in vitro (Q34565122) (← links)
- ESAT-6 (EsxA) and TB10.4 (EsxH) based vaccines for pre- and post-exposure tuberculosis vaccination (Q35069386) (← links)
- Pro- and anti-inflammatory cytokines against Rv2031 are elevated during latent tuberculosis: a study in cohorts of tuberculosis patients, household contacts and community controls in an endemic setting (Q35514492) (← links)
- HspX-mediated protection against tuberculosis depends on its chaperoning of a mycobacterial molecule (Q36439241) (← links)
- The Mycobacterium bovis BCG prime-Rv0577 DNA boost vaccination induces a durable Th1 immune response in mice (Q36949611) (← links)
- Systems approach to tuberculosis vaccine development (Q38075096) (← links)
- Recombinant BCG: Innovations on an Old Vaccine. Scope of BCG Strains and Strategies to Improve Long-Lasting Memory (Q38207991) (← links)
- Prime-boost vaccination strategy with bacillus Calmette-Guérin (BCG) and liposomized alpha-crystalline protein 1 reinvigorates BCG potency (Q39021341) (← links)
- Microstructured liposome subunit vaccines reduce lung inflammation and bacterial load after Mycobacterium tuberculosis infection. (Q39533200) (← links)
- Adjunctive immunotherapy with α-crystallin based DNA vaccination reduces Tuberculosis chemotherapy period in chronically infected mice (Q40608583) (← links)
- A lipidated peptide of Mycobacterium tuberculosis resuscitates the protective efficacy of BCG vaccine by evoking memory T cell immunity (Q41922740) (← links)
- Enhanced protective efficacy against Mycobacterium tuberculosis afforded by BCG prime-DNA boost regimen in an early challenge mouse model is associated with increased splenic interleukin-2-producing CD4 T-cell frequency post-vaccination (Q42210000) (← links)
- Boosting with recombinant MVA expressing M. tuberculosis α-crystallin antigen augments the protection imparted by BCG against tuberculosis in guinea pigs (Q47155139) (← links)
- Multi-stage subunit vaccines against Mycobacterium tuberculosis: an alternative to the BCG vaccine or a BCG-prime boost? (Q47834561) (← links)
- TLR2-targeted secreted proteins from Mycobacterium tuberculosis are protective as powdered pulmonary vaccines (Q47950164) (← links)
- Invited review: guinea pig models for translation of DOHaD into the clinic. (Q52597213) (← links)
- A lipidated bi-epitope vaccine comprising of MHC-I and MHC-II binder peptides elicits protective CD4 T cell and CD8 T cell immunity against Mycobacterium tuberculosis (Q57281139) (← links)
- Enhancing immunogenicity of novel multistage subunit vaccine of Mycobacterium tuberculosis using PLGA:DDA hybrid nanoparticles and MPLA: Subcutaneous administration (Q90448187) (← links)